Wu Z, Mcgoogan JM. Characteristics of and Important Lessons From the Coronavirus Disease 2019 (COVID-19) Outbreak in China: Summary of a Report of 72 314 Cases From the Chinese Center for Disease Control and Prevention. JAMA, 2020
Wang DW, Hu B, Hu C, et al. Clinical Characteristics of 138 Hospitalized Patients With 2019 Novel Coronavirus-Infected Pneumonia in Wuhan, China. JAMA, 2020,323(11):1061–1069
CAS
Article
Google Scholar
Zhou P, Yang X, Wang X, et al. A pneumonia outbreak associated with a new coronavirus of probable bat origin. Nature, 2020,579(7798):270–273
CAS
Article
Google Scholar
Huang C, Wang Y, Li X, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet, 2020,395(10223):497–506
CAS
Article
Google Scholar
Yao XH, Li TY, He ZC, et al. A pathological report of three COVID-19 cases by minimally invasive autopsies. Zhonghua Bing Li Xue Za Zhi (Chinese), 2020,49(0):E009
Google Scholar
Wang C, Horby PW, Hayden FG, et al. A novel coronavirus outbreak of global health concern. Lancet, 2020,395(10223):470–473
CAS
Article
Google Scholar
National Health Commission. The guidelines for the diagnosis and treatment of 2019 novel coronavirus (2019-nCoV) infection (Pilot 7rd version). [S/OL]. 2020(2020-03-03).
Chen N, Zhou M, Dong X, et al. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. Lancet, 2020,395(10223):507–513
CAS
Article
Google Scholar
Cao B, Wang Y, Wen D, et al. A Trial of Lopinavir-Ritonavir in Adults Hospitalized with Severe Covid-19. N Engl J Med, 2020,382(19):1787–1799
Article
Google Scholar
Hernandez AV, Roman YM, Pasupuleti V, et al. Hydroxychloroquine or Chloroquine for Treatment or Prophylaxis of COVID-19: A Living Systematic Review. Ann Int Med, 2020.
Deng L, Li C, Zeng Q, et al. Arbidol combined with LPV/r versus LPV/r alone against Corona Virus Disease 2019: A retrospective cohort study. J Infect, 2020,81(1):e1–e5
CAS
Article
Google Scholar
Zhu Z, Lu Z, Xu T, et al. Arbidol monotherapy is superior to lopinavir/ritonavir in treating COVID-19. J Infect, 2020,81(1):e21–e23
CAS
Article
Google Scholar
Beigel JH, Tomashek KM, Dodd LE, et al. Remdesivir for the Treatment of Covid-19 — Preliminary Report. N Engl J Med, 2020:NEJMoa2007764
Grein J, Ohmagari N, Shin D, et al. Compassionate Use of Remdesivir for Patients with Severe Covid-19. N Engl J Med, 2020,382(24):2327–2336
CAS
Article
Google Scholar
Fan E, Del Sorbo L, Goligher EC, et al. An Official American Thoracic Society/European Society of Intensive Care Medicine/Society of Critical Care Medicine Clinical Practice Guideline: Mechanical Ventilation in Adult Patients with Acute Respiratory Distress Syndrome. Am J Respir Crit Care Med, 2017,195(9):1253–1263
Article
Google Scholar
Ledford H. Coronavirus breakthrough: dexamethasone is first drug shown to save lives [published online ahead of print, 2020 Jun 16]. Nature, 2020:https://doi.org/10.1038/d41586-020-01824-5
Abdolahi N, Kaheh E, Golsha R, et al. Letter to the editor: efficacy of different methods of combination regimen administrations including dexamethasone, intravenous immunoglobulin, and interferon-beta to treat critically ill COVID-19 patients: a structured summary of a study protocol for a randomized controlled trial. Trials, 2020,21(1):549
CAS
Article
Google Scholar